Rapport: "Embryonale stamceller". - Teknologirådet

Embryonale stamceller – høring om anvendelse af stamceller i forskning og behandling 23. januar 2003
Indholdsfortegnelse
FORORD...........................................................................................................................................................................1
RESUMÉ...........................................................................................................................................................................2
HVAD ER STAMCELLER?....................................................................................................................................................2
TRE SKRIDT FREM OG TO TILBAGE ......................................................................................................................................2
ANTALLET AF BEFRUGTEDE ÆG..........................................................................................................................................3
VOKSNE ELLER EMBRYONALE STAMCELLER .........................................................................................................................3
INDIVIDUELT MENNESKELIGT LIV ......................................................................................................................................4
TINGSLIGGØRELSE AF LIV..................................................................................................................................................4
FORSKELLIGE LOV-MODELLER............................................................................................................................................5
INTERESSER OG RETTIGHEDER ...........................................................................................................................................5
DET FORSKNINGSMÆSSIGE POTENTIALE.............................................................................................................................6
BETACELLER TIL DIABETES.................................................................................................................................................7
SPØRGSMÅL OM RISICI .....................................................................................................................................................7
DEBAT OM MENNESKELIGT LIV .........................................................................................................................................8
DE ERHVERVSMÆSSIGE PERSPEKTIVER...............................................................................................................................8
PATENT PÅ CELLELINIER....................................................................................................................................................9
GRUNDFORSKNING ELLER BEHANDLING ............................................................................................................................9
DE SUNDHEDSMÆSSIGE PERSPEKTIVER............................................................................................................................10
ET LANDSDÆKKENDE REGISTER.......................................................................................................................................10
DEBAT OM RESSOURCER .................................................................................................................................................11
DE SAMFUNDSMÆSSIGE RAMMER...................................................................................................................................12
UDVIDELSE AF ETIK-BEGREBET........................................................................................................................................12
BÅDE FOREBYGGELSE OG BEHANDLING............................................................................................................................13
KILDEN TIL STAMCELLER.................................................................................................................................................14
REDIGERET UDSKRIFT AF HØRING OM EMBRYONALE STAMCELLER ............................................................. 15
VELKOMST....................................................................................................................................................................15
HELGE SANDER, MINISTER FOR VIDENSKAB, TEKNOLOGI OG UDVIKLING:
VIDEN OM STAMCELLER ............................................................................................................................................17
STEN EIRIK JACOBSEN, PROFESSOR, MD, PH.D, LUND UNIVERSITET:.................................................................................17
PETER HOKLAND, OVERLÆGE, DR.MED., ÅRHUS AMTSSYGEHUS: ......................................................................................19
DE ETISKE OG REGULERINGSMÆSSIGE SPØRGSMÅL............................................................................................29
SVEND ANDERSEN, PROFESSOR, DR.THEOL., CENTER FOR BIOETIK, AARHUS UNIVERSITET: .................................................29
KERSTIN HOFFMAN, CAND.MED., LANDSSEKRETÆR FOR FORENINGEN RETTEN TIL LIV: .......................................................31
METTE HARTLEV , LEKTOR, PH.D., KØBENHAVNS UNIVERSITET, NÆSTFORMAND I DET ETISKE RÅD: ...................................33
DET FORSKNINGSMÆSSIGE POTENTIALE...............................................................................................................44
JENS ZIMMER RASMUSSEN, PROFESSOR DR.MED., DANSK CENTER FOR STAMCELLEFORSKNING: ..........................................44
OLE MADSEN, FORSKNINGSCHEF, PH.D., HAGEDORN RESEARCH INSTITUTE: .....................................................................47
DE ERHVERVSMÆSSIGE PERSPEKTIVER..................................................................................................................62
MADS KROGSGAARD THOMSEN, FORSKNINGSDIREKTØR, PROFESSOR, DR.MED.VET., NOVO NORDISK .................................62
METTE KIRSTINE AGGER, ADMINISTRERENDE DIREKTØR, 7TM PHARMA: .........................................................................65